These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466 [TBL] [Abstract][Full Text] [Related]
23. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334 [TBL] [Abstract][Full Text] [Related]
24. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Sattler M; Scheijen B; Weisberg E; Griffin JD Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554 [TBL] [Abstract][Full Text] [Related]
26. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789 [TBL] [Abstract][Full Text] [Related]
27. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Sattler M; Salgia R; Shrikhande G; Verma S; Choi JL; Rohrschneider LR; Griffin JD Oncogene; 1997 Nov; 15(19):2379-84. PubMed ID: 9393882 [TBL] [Abstract][Full Text] [Related]
28. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. O'Dwyer ME; Druker BJ Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636 [TBL] [Abstract][Full Text] [Related]
29. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921 [TBL] [Abstract][Full Text] [Related]
31. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. Mazzacurati L; Pattacini L; Brusa G; Mancini M; Benvenuti M; Barbieri E; Martinelli G; Baccarani M; Greenberger JS; Santucci MA Hematol J; 2004; 5(2):168-77. PubMed ID: 15048068 [TBL] [Abstract][Full Text] [Related]
32. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252 [TBL] [Abstract][Full Text] [Related]
33. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia. Salesse S; Verfaillie CM Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034 [TBL] [Abstract][Full Text] [Related]
34. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor]. Nakajima M; Toga W Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002 [TBL] [Abstract][Full Text] [Related]
35. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. Liu WM; Stimson LA; Joel SP Br J Cancer; 2002 May; 86(9):1472-8. PubMed ID: 11986783 [TBL] [Abstract][Full Text] [Related]
37. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Carter BZ; Mak DH; Shi Y; Schober WD; Wang RY; Konopleva M; Koller E; Dean NM; Andreeff M Cell Cycle; 2006 Oct; 5(19):2223-9. PubMed ID: 16969080 [TBL] [Abstract][Full Text] [Related]
38. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129 [TBL] [Abstract][Full Text] [Related]
39. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Kasper B; Fruehauf S; Schiedlmeier B; Buchdunger E; Ho AD; Zeller WJ Cancer Chemother Pharmacol; 1999; 44(5):433-8. PubMed ID: 10501919 [TBL] [Abstract][Full Text] [Related]
40. Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression. Nakamura S; Yokota D; Tan L; Nagata Y; Takemura T; Hirano I; Shigeno K; Shibata K; Fujisawa S; Ohnishi K Int J Cancer; 2012 Mar; 130(5):1046-59. PubMed ID: 21400515 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]